Friedreich Ataxia Clinical Trials

15 recruiting

Friedreich Ataxia Trials at a Glance

15 actively recruiting trials for friedreich ataxia are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Philadelphia, Paris, and Los Angeles. Lead sponsors running friedreich ataxia studies include Biogen, Centre Hospitalier Universitaire de Nice, and Design Therapeutics, Inc..

Browse friedreich ataxia trials by phase

Treatments under study

About Friedreich Ataxia Clinical Trials

Looking for clinical trials for Friedreich Ataxia? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Friedreich Ataxia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Friedreich Ataxia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting

Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia

Friedreich Ataxia
Centre Hospitalier Universitaire de Nice40 enrolled1 locationNCT07013292
Recruiting

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

Friedreich Ataxia
Biogen300 enrolled14 locationsNCT06623890
Recruiting

Clinical Course Of Disease In Participants With FA-CM

CardiomyopathyFriedreich Ataxia
Lexeo Therapeutics65 enrolled14 locationsNCT06865482
Recruiting

Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia

Friedreich Ataxia
German Center for Neurodegenerative Diseases (DZNE)200 enrolled6 locationsNCT05943002
Recruiting
Phase 1

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

CardiomyopathiesFriedreich AtaxiaMyocardial Fibrosis+1 more
Weill Medical College of Cornell University25 enrolled1 locationNCT05302271
Recruiting

Friedreich Ataxia Nerve Ultrasund

Friedreich Ataxia
Centre Hospitalier Universitaire de Nice14 enrolled1 locationNCT07508631
Recruiting
Phase 2

An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

Friedreich Ataxia
Larimar Therapeutics, Inc.85 enrolled8 locationsNCT06447025
Recruiting
Phase 3

A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)

Friedreich Ataxia
Biogen255 enrolled34 locationsNCT06953583
Recruiting
Phase 1

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

Friedreich Ataxia
Biogen35 enrolled1 locationNCT06054893
Recruiting

A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

Friedreich Ataxia
Biogen20 enrolled1 locationNCT06628687
Recruiting

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

Friedreich Ataxia
Friedreich's Ataxia Research Alliance3,000 enrolled34 locationsNCT06016946
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Rare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence+188 more
Sanford Health20,000 enrolled2 locationsNCT01793168
Recruiting
Phase 1Phase 2

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

Friedreich Ataxia
Design Therapeutics, Inc.20 enrolled3 locationsNCT06874010
Recruiting

Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia

Friedreich Ataxia
Institut National de la Santé Et de la Recherche Médicale, France70 enrolled1 locationNCT05874388
Recruiting
Not Applicable

Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's Ataxia

Friedreich Ataxia
IRCCS Eugenio Medea24 enrolled1 locationNCT06692296